Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Stephanie Brumfield"'
Autor:
Zheng Tan, Steve Sorota, Deen Tulshian, R. Jason Herr, William G. Earley, Charles R. Heap, Stephanie Brumfield, Terry Bridal, Jennifer Hanisak, Xiaoping Zhou, Julius Matasi, Ana Bercovici, Ginny D. Ho, Diane Rindgen, Brandy Courneya, Shu-Wei Yang
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:4110-4113
A series of pyrrolo-benzo-1,4-diazine analogs have been synthesized and displayed potent Nav1.7 inhibitory activity and moderate selectivity over Nav1.5. The syntheses, structure-activity relationships, and selected pharmacokinetic data of these anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01754d087a669b8aba1f63615bf091ab
https://doi.org/10.1016/j.bmcl.2014.07.060
https://doi.org/10.1016/j.bmcl.2014.07.060
Autor:
Julius J. Matasi, Stephanie Brumfield, Deen Tulshian, Michael Czarnecki, William Greenlee, Charles G. Garlisi, Hongchen Qiu, Kristine Devito, Shu-Cheng Chen, Youngliang Sun, Rosalia Bertorelli, William Geiss, Van-Duc Le, Gregory S. Martin, Samuel A. Vellekoop, James Haber, Melissa L. Allard
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:3805-3808
Structure-activity relationship (SAR) efforts around our initial lead compound 1 led to the identification of potent P2X(7) receptor antagonists with improved pharmacokinetic profiles. These compounds were potent and selective at the P2X(7) receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12eb025e3d5e21bb6c67880ae2ad4913
https://doi.org/10.1016/j.bmcl.2011.04.034
https://doi.org/10.1016/j.bmcl.2011.04.034
Autor:
Peter Korakas, Duane A. Burnett, Rosalia Bertorelli, Gianluca Lozza, Stephanie Brumfield, T.K. Sasikumar, Cheng Li, Angelo Reggiani, Chad Bennett, Martin S. Domalski, Lisa S. Silverman, Wen-Lian Wu, Li Qiang, Julius Matasi, Chad E. Knutson, Deen Tulshian, Mariagrazia Grilli, William J. Greenlee
Publikováno v:
Bioorganicmedicinal chemistry letters. 22(23)
High throughput screening identified the pyridothienopyrimidinone 1 as a ligand for the metabotropic glutamate receptor 1 (mGluR1=10 nM). Compound 1 has an excellent in vivo profile; however, it displays unfavorable pharmacokinetic issues and metabol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b067b63e4caa75f87ad61d50f4143220
https://pubmed.ncbi.nlm.nih.gov/23084894
https://pubmed.ncbi.nlm.nih.gov/23084894
Autor:
Stephanie Brumfield, Julius J. Matasi, Deen Tulshian, Michael Czarniecki, William Greenlee, Charles Garlisi, Hongchen Qiu, Kristine Devito, Shu-Cheng Chen, Yongliang Sun, Rosalia Bertorelli, Justin Ansell, William Geiss, Van-Duc Le, Gregory S. Martin, Samuel A. Vellekoop, James Haber, Melissa L. Allard
Publikováno v:
Bioorganicmedicinal chemistry letters. 21(24)
Novel P2X(7) antagonists were developed using a purine scaffold. These compounds were potent and selective at the P2X(7) receptor in human and rodent as well as efficacious in rodent pain models. Compound 15a was identified to have oral potency in se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7ebe62239fe0e5063260d2fbbb27b57
https://pubmed.ncbi.nlm.nih.gov/22078214
https://pubmed.ncbi.nlm.nih.gov/22078214